These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
404 related articles for article (PubMed ID: 26219291)
1. The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review. Dias P; Penedones A; Alves C; Ribeiro CF; Marques FB Curr Drug Saf; 2015; 10(3):234-50. PubMed ID: 26219291 [TBL] [Abstract][Full Text] [Related]
2. Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase Vogel U; van Stekelenborg J; Dreyfus B; Garg A; Habib M; Hosain R; Wisniewski A Drug Saf; 2020 Apr; 43(4):351-362. PubMed ID: 32020559 [TBL] [Abstract][Full Text] [Related]
3. Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports. Trippe ZA; Brendani B; Meier C; Lewis D Drug Saf; 2017 Apr; 40(4):293-303. PubMed ID: 28130773 [TBL] [Abstract][Full Text] [Related]
4. An experimental investigation of masking in the US FDA adverse event reporting system database. Wang HW; Hochberg AM; Pearson RK; Hauben M Drug Saf; 2010 Dec; 33(12):1117-33. PubMed ID: 21077702 [TBL] [Abstract][Full Text] [Related]
5. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions. Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924 [TBL] [Abstract][Full Text] [Related]
6. Is pharmacovigilance of biologicals cost-effective? Claus B Int J Clin Pharm; 2018 Aug; 40(4):787-789. PubMed ID: 30051230 [TBL] [Abstract][Full Text] [Related]
7. Comparison of statistical signal detection methods within and across spontaneous reporting databases. Candore G; Juhlin K; Manlik K; Thakrar B; Quarcoo N; Seabroke S; Wisniewski A; Slattery J Drug Saf; 2015 Jun; 38(6):577-87. PubMed ID: 25899605 [TBL] [Abstract][Full Text] [Related]
8. Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles? Michel C; Scosyrev E; Petrin M; Schmouder R Clin Drug Investig; 2017 May; 37(5):415-422. PubMed ID: 28224371 [TBL] [Abstract][Full Text] [Related]
9. Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance. Zink RC; Huang Q; Zhang LY; Bao WJ Chin J Nat Med; 2013 May; 11(3):314-20. PubMed ID: 23725848 [TBL] [Abstract][Full Text] [Related]
10. EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies. Francescon S; Fornasier G; Baldo P Int J Clin Pharm; 2018 Aug; 40(4):778-782. PubMed ID: 30094558 [TBL] [Abstract][Full Text] [Related]
11. Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations. Caster O; Aoki Y; Gattepaille LM; Grundmark B Drug Saf; 2020 May; 43(5):479-487. PubMed ID: 32008183 [TBL] [Abstract][Full Text] [Related]
12. Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area. Grundmark B; Holmberg L; Garmo H; Zethelius B Eur J Clin Pharmacol; 2014 May; 70(5):627-35. PubMed ID: 24599513 [TBL] [Abstract][Full Text] [Related]
13. The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project. Raschi E; Poluzzi E; Salvo F; Koci A; Suling M; Antoniazzi S; Perina L; Hazell L; Moretti U; Sturkenboom M; Garbe E; Pariente A; De Ponti F Drug Saf; 2016 Jan; 39(1):59-68. PubMed ID: 26446144 [TBL] [Abstract][Full Text] [Related]
14. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems. Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026 [TBL] [Abstract][Full Text] [Related]
15. Pharmacovigilance in China: development and challenges. Zhao Y; Wang T; Li G; Sun S Int J Clin Pharm; 2018 Aug; 40(4):823-831. PubMed ID: 30051225 [TBL] [Abstract][Full Text] [Related]
16. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421 [TBL] [Abstract][Full Text] [Related]
17. Validation of statistical signal detection procedures in eudravigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling. Alvarez Y; Hidalgo A; Maignen F; Slattery J Drug Saf; 2010 Jun; 33(6):475-87. PubMed ID: 20486730 [TBL] [Abstract][Full Text] [Related]
18. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib. Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646 [TBL] [Abstract][Full Text] [Related]
19. Pilot evaluation of an automated method to decrease false-positive signals induced by co-prescriptions in spontaneous reporting databases. Avillach P; Salvo F; Thiessard F; Miremont-Salamé G; Fourrier-Reglat A; Haramburu F; Bégaud B; Moore N; Pariente A; Pharmacoepidemiol Drug Saf; 2014 Feb; 23(2):186-94. PubMed ID: 23670805 [TBL] [Abstract][Full Text] [Related]
20. Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase. Sandberg L; Taavola H; Aoki Y; Chandler R; Norén GN Drug Saf; 2020 Oct; 43(10):999-1009. PubMed ID: 32564242 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]